Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Proactive Investors | Interview with Amplia CEO Chris Burns on clinical trial progress
Fifth partial response confirmed in ACCENT trial
Amplia receives R&D Tax Rebate
Key chemical form patents in Europe and Japan
Fourth partial response confirmed in ACCENT trial
ASX Briefs podcast | Interview with Dr Chris Burns
Categories
Archive
Company News
Investor Newsletters
Videos
06 Feb 2023
ABC Media Coverage | Pancreatic cancer clinical trial opens in Queensland, offering hope to patients
Read More
01 Feb 2023
First Patient Recruited to Cohort 2 of ACCENT Trial in Pancreatic Cancer
Read More
30 Jan 2023
PROACTIVE INTERVIEW | Dr Chris Burns
Read More
11 Jan 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Read More
08 Dec 2022
Meet the CEO | Dr Chris Burns
Read More
29 Nov 2022
ACCENT Trial Recruitment Progress
Read More
03 Oct 2022
AMP886 Activity in Acute Myeloid Leukemia (AML)
Read More
28 Sep 2022
Stockhead Investor Guide
Read More
18 Aug 2022
Channel 9 | Clinical Trial Recruitment
Read More
18 Aug 2022
The Australian | Drug to tear down tumour defences
Read More
18 Aug 2022
The Front Podcast | 18 August 2022
Read More
18 Aug 2022
MEDIA RELEASE | Australian-made treatment for pancreatic cancer – clinical trial milestone
Read More
02 Aug 2022
First patient recruited into ACCENT trial
Read More
28 Jul 2022
QUARTERLY REPORT & 4C
Read More
29 Jun 2022
The science of manufacturing, at scale
Read More
23 Jun 2022
Navigating human research ethics
Read More
09 May 2022
ABC News | Bioshares
Read More
19 Apr 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
07 Apr 2022
VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial
Read More
05 Apr 2022
New investment in pancreatic cancer research
Read More
1
2
3
4
5